Literature DB >> 33479910

Regulatory and IgE+ B Cells in Allergic Asthma.

John Paul Oliveria1,2, Rita Agayby2, Gail M Gauvreau3.   

Abstract

Allergic asthma is triggered by inhalation of environmental allergens resulting in bronchial constriction and inflammation, which leads to clinical symptoms such as wheezing, coughing, and difficulty breathing. Asthmatic airway inflammation is initiated by inflammatory mediators released by granulocytic cells. However, the immunoglobulin E (IgE) antibody is necessary for the initiation of the allergic cascade, and IgE is produced and released exclusively by memory B cells and plasma cells. Acute allergen exposure has also been shown to increase IgE levels in the airways of patients diagnosed with allergic asthma; however, more studies are needed to understand local airway inflammation. Additionally, regulatory B cells (Bregs) have been shown to modulate IgE-mediated inflammatory processes in allergic asthma pathogenesis, particularly in mouse models of allergic airway disease. However, the levels and function of these IgE+ B cells and Bregs remain to be elucidated in human models of asthma. The overall objective for this chapter is to provide detailed methodological, and insightful technological advances to study the biology of B cells in allergic asthma pathogenesis. Specifically, we will describe how to investigate the frequency and function of IgE+ B cells and Bregs in allergic asthma, and the kinetics of these cells after allergen exposure in a human asthma model.

Entities:  

Keywords:  Airway inflammation; Allergic asthma; Human immunology; IgE+ B cells; Inhaled allergen challenge; Regulatory B cells; Sputum

Mesh:

Substances:

Year:  2021        PMID: 33479910     DOI: 10.1007/978-1-0716-1237-8_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  104 in total

Review 1.  Immunologic basis of antigen-induced airway hyperresponsiveness.

Authors:  M Wills-Karp
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

2.  Asthmatic subjects with allergy have elevated levels of IgE+ B cells in the airways.

Authors:  John-Paul Oliveria; Brittany M Salter; Stephanie Phan; Caitlin D Obminski; Caroline E Munoz; Steven G Smith; Tara Scime; Rick M Watson; Roma Sehmi; Gail M Gauvreau
Journal:  J Allergy Clin Immunol       Date:  2017-02-16       Impact factor: 10.793

3.  Increased IgE+ B Cells in Sputum, but Not Blood, Bone Marrow, or Tonsils, after Inhaled Allergen Challenge in Subjects with Asthma.

Authors:  John-Paul Oliveria; Brittany M Salter; Jonathan MacLean; Shweta Kotwal; Ashley Smith; Jeffrey M Harris; Heleen Scheerens; Roma Sehmi; Gail M Gauvreau
Journal:  Am J Respir Crit Care Med       Date:  2017-07-01       Impact factor: 21.405

4.  Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.

Authors:  Gail M Gauvreau; Jeffrey M Harris; Louis-Philippe Boulet; Heleen Scheerens; J Mark Fitzgerald; Wendy S Putnam; Donald W Cockcroft; Beth E Davis; Richard Leigh; Yanan Zheng; Barbro Dahlén; Yehong Wang; Romeo Maciuca; Irvin Mayers; X Charlene Liao; Lawren C Wu; John G Matthews; Paul M O'Byrne
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

5.  Measuring Eosinophils to Make Treatment Decisions in Asthma.

Authors:  Parameswaran Nair; Paul M O'Byrne
Journal:  Chest       Date:  2016-09       Impact factor: 9.410

6.  Ligelizumab for Chronic Spontaneous Urticaria.

Authors:  Marcus Maurer; Ana M Giménez-Arnau; Gordon Sussman; Martin Metz; Diane R Baker; Andrea Bauer; Jonathan A Bernstein; Randolf Brehler; Chia-Yu Chu; Wen-Hung Chung; Inna Danilycheva; Clive Grattan; Jacques Hébert; Constance Katelaris; Michael Makris; Raisa Meshkova; Sinisa Savic; Rodney Sinclair; Karl Sitz; Petra Staubach; Bettina Wedi; Jürgen Löffler; Avantika Barve; Kenneth Kobayashi; Eva Hua; Thomas Severin; Reinhold Janocha
Journal:  N Engl J Med       Date:  2019-10-03       Impact factor: 91.245

Review 7.  The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.

Authors:  Stephen Holgate; Thomas Casale; Sally Wenzel; Jean Bousquet; Yamo Deniz; Colin Reisner
Journal:  J Allergy Clin Immunol       Date:  2005-03       Impact factor: 10.793

8.  Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.

Authors:  Gail M Gauvreau; Jonathan P Arm; Louis-Philippe Boulet; Richard Leigh; Donald W Cockcroft; Beth E Davis; Irvin Mayers; J Mark FitzGerald; Barbro Dahlen; Kieran J Killian; Michel Laviolette; Christopher Carlsten; Nikolaos Lazarinis; Richard M Watson; Joanne Milot; Veronica Swystun; Miranda Bowen; Linda Hui; Ann-Sofie Lantz; Karin Meiser; Suzanne Maahs; Philip J Lowe; Andrej Skerjanec; Anton Drollmann; Paul M O'Byrne
Journal:  J Allergy Clin Immunol       Date:  2016-04-07       Impact factor: 10.793

Review 9.  Allergen inhalation challenge: a human model of asthma exacerbation.

Authors:  Gail M Gauvreau; Michelle Y Evans
Journal:  Contrib Microbiol       Date:  2007

Review 10.  Interleukin-13 in asthma pathogenesis.

Authors:  Marsha Wills-Karp
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.